<DOC>
	<DOCNO>NCT00473642</DOCNO>
	<brief_summary>In pilot study researcher evaluate safety efficacy 50 % reduce fluence PDT combination therapy ranibizumab . The researcher hope gain information regard use reduce fluence PDT combination therapy . The information gain pilot study may prompt definitive study compare safety efficacy standard fluence PDT combination therapy , reduce fluence PDT combination therapy , ranibizumab monotherapy . The study compare use combination therapy ranibizumab verteporfin PDT ranibizumab alone patient exudative age-related macular degeneration ( AMD ) . All patient receive three consecutive monthly treatment ranibizumab . Patients randomize 1:1:1 3 group . Patients randomize group 1 receive ranibizumab . Patients randomize group 2 also receive one treatment reduce fluence ( 50 % fluence ) verteporfin PDT day 0 . Patients randomize group 3 also receive one treatment standard fluence verteporfin PDT . All patient also evaluate possible retreatment ranibizumab verteporfin PDT accord establish criterion . Thirty patient recruit one U.S. sit . Randomization occur time entry study . Follow-up continue month 12 ( day 0 ) subject .</brief_summary>
	<brief_title>Reduced Fluence Photodynamic Therapy ( PDT ) With Visudyne Combination With Lucentis Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>1 . Male Female Patients &gt; 50 year age . 2 . Patients primary subfoveal CNV secondary AMD document IVFA and/or OCT. 3 . Patient BCVA 20/40 20/320 study eye use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart . See definition ETDRS chart . 4 . If eye eligible , one eye evaluate study . The eye less visual acuity select study eye . 5 . Patients must able willing provide write informed consent . 1 . Patients receive prior treatment study eye verteporfin , focal laser photocoagulation , vitrectomy , intravitreous injection antiangiogenic medication , include triamcinolone , pegaptanib , bevacizumab , ranibizumab . 2 . Neovascular membrane retinal disease myopic degeneration , histoplasmosis , retinal angiomatous proliferation , ocular inflammatory disease . 3 . Choroidal neovascular membrane great 9 disc diameter size . 4 . Previous posterior vitrectomy study eye . 5 . Concurrent disease study eye could compromise visual acuity require medical surgical intervention study period . 6 . Pregnant woman premenopausal woman use adequate contraception . 7 . History allergy fluorescein , Visudyne , Lucentis . 8 . Inability comply study follow procedure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Verteporfin</keyword>
	<keyword>Visudyne</keyword>
	<keyword>Photodynamic therapy</keyword>
</DOC>